Athletes with mild hypertrophic cardiomyopathy (HCM) at low risk of sudden cardiac death (SCD) can safely continue to exercise at competitive levels, a retrospective study suggests. During a mean ...

MIAMI--(BUSINESS WIRE)--Human Capital Management (HCM) software is one of many technologies being influenced by mass resignation and an uncertain employment landscape. Challenges in hiring and ...

ATLANTA, GA—Ninerafaxstat (Imbria Pharmaceuticals), a novel drug targeted at patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), is safe and well tolerated, according to data ...

In this article we are going to use hedge fund sentiment as a tool and determine whether Hutchison China MediTech Limited (NASDAQ:HCM) is a good investment right now. We like to analyze hedge fund ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 ...

SONATA-HCM is the only ongoing Phase 3 study in both obstructive and non-obstructive HCM. It is a randomized, double-blind, placebo-controlled multicenter trial that will evaluate the efficacy of ...

MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that VALOR-HCM, the Phase 3 randomized, double-blind, placebo-controlled study evaluating mavacamten in adults with ...

– In a Phase 1 in healthy subjects, EDG-7500 was well-tolerated without meaningful changes in left ventricle ejection fraction (LVEF) – – CIRRUS-HCM single-dose trial of EDG-7500 in obstructive HCM ...

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers Michael E. Nassif, M.D., Cardiologist, ...

Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon ...